...
首页> 外文期刊>Applied Microbiology and Biotechnology >A novel process for the production of a veterinary rabies vaccine in BHK-21 cells grown on microcarriers in a 20-l bioreactor
【24h】

A novel process for the production of a veterinary rabies vaccine in BHK-21 cells grown on microcarriers in a 20-l bioreactor

机译:在20升生物反应器中的微载体上生长的BHK-21细胞中生产兽用狂犬病疫苗的新方法

获取原文
获取原文并翻译 | 示例

摘要

We studied BHK-21 cells growth in a 2-l bioreactor and investigated the effects of microcarrier concentration, type of growth medium, culture mode and serum concentration. The highest cell density reached was equal to 4×106 cells/ml and was achieved in minimum essential medium supplemented with Hanks' salts, non-essential amino acids and 5% fetal calf serum, using a perfusion culture mode and a microcarrier concentration of 4 g Cytodex 3/l. We studied rabies virus production (PV/BHK-21 strain) by BHK-21 cells grown at the optimal conditions determined previously. We analyzed the effects of multiplicity of infection (MOI) and type of medium used for virus multiplication in spinner-flasks and showed that the highest virus titer reached (when the cells were infected at a MOI of 0.3) in M199 medium supplemented with 0.2% of bovine serum albumin was equal to 8.2×107 Fluorescent Focus Units (FFU)/ml. When we grew the cells in a 2-l perfused bioreactor, we obtained a maximal virus titer of 3×108 FFU/ml. In addition, we scaled-up to a 20-l bioreactor and obtained similar results for cell density and virus titer. The experimental vaccine we developed meets WHO requirements for vaccine potency. Each run yielded about 40,000 doses of potent vaccine.
机译:我们研究了BHK-21细胞在2-l生物反应器中的生长,并研究了微载体浓度,生长培养基类型,培养模式和血清浓度的影响。达到最高细胞密度等于4×106 / ml,并通过灌注培养模式和离心法在添加Hanks盐,非必需氨基酸和5%胎牛血清的最小必需培养基中达到。微载体浓度为4 g Cytodex 3 / l。我们研究了在先前确定的最佳条件下生长的BHK-21细胞产生的狂犬病病毒(PV / BHK-21株)。我们分析了感染复数(MOI)的影响以及用于旋转瓶中病毒繁殖的培养基类型的影响,结果表明,在添加0.2%的M199培养基中,病毒滴度达到了最高(当细胞以MOI感染0.3时)牛血清白蛋白的含量等于8.2×107 荧光聚焦单位(FFU)/ ml。当我们在2-l灌注的生物反应器中培养细胞时,我们获得的最大病毒滴度为3×108 FFU / ml。此外,我们将规模扩大到20升生物反应器,并获得了类似的细胞密度和病毒滴度结果。我们开发的实验疫苗符合WHO对疫苗效力的要求。每次运行产生约40,000剂有效疫苗。

著录项

  • 来源
    《Applied Microbiology and Biotechnology》 |2003年第6期|441-446|共6页
  • 作者单位

    Viral Vaccines Research and Development Unit Institute Pasteur;

    Viral Vaccines Research and Development Unit Institute Pasteur;

    Viral Vaccines Research and Development Unit Institute Pasteur;

    Viral Vaccines Research and Development Unit Institute Pasteur;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号